								She	eet <u>1</u> of <u>7</u>	
U.S. DEPARTMENT OF COMMERCE					ATTY. DOCKET NO. 20150-74359			SERIAL NO. 10/765,336		
	PATENT AND TRADEMARK OFFICE					APPLICANT				
	NEODN	IATION DISCLOSURE STAT	EMENT		Iontcho Vla			00000		
	INFORM	IATION DISCLOSURE STAT	EIVIEN I		FILING DATE 1/27/2004			GROUP 1616		
			U.S. PATEN	T DO	CUMENTS					
*Examiner		Document Number	Date	Γ	Name	Class	Su	bclass	Filing Date	
Initial	AA	5,672,486	9/30/1997	So.	ulillou	Caso	-		if Appropriate	
	AB	4,691.024	9/1/1987	-	ahata		╁		-	
	AC	4,713,249	12/15/1987		roder	<del>                                     </del>	$\vdash$			
	AD	5,266,333	11/30/1993	Cae		<b>†</b>	1			
	AE	5,417,982	5/23/1995	Mo	<del></del>		T			
	AF	-,,		_			1			
	AG						$\vdash$			
	AH						T			
	Al			_			T			
	AJ						T			
	AK									
			FOREIGN PATI	ENT I	DOCUMENTS	;				
		Document Number	Date		Country	Class	Su	bclass	Translation Yes No	
	AL									
	AM									
	AN									
	AO									
	AP									
	AQ							•		
		OTHER REFERENC								
	AR	Anderson et al., "Potocytos 410-411 (1992).	· ·				les b	y caveolae	e," Science 255:	
	AS	Antony, A. C., "Folate receptors," Annu Rev Nutr, 16: 501-21 (1996).								
	AT	Antony, A. C., "The biologic	cal chemistry of	folate	e receptors," i	Blood 79(11):	2807	-2820 (199	92).	
	AU	Barnett et al., "Structure-Admide (Vindesine) Sulfate	Barnett et al., "Structure-Activity Relationships of Dimeric Catharanthus Alkaloids. 1. Deacetylvinblastine Amide (Vindesine) Sulfate," <i>J. Med. Chem.</i> 21: 88-96 (1978).							
	AV	Boger, D.L., et al., "1,2,9,9 Analogue of the CC-1065	a-Tetrahydrocy	clopro	pa[ c  benz[ e	lindol-4-one	(CBI)	: A Simplif	fied	
	AW	Campbell et al., "Folate-bin							5329-5338 (1991).	
	AX	Cho et al., "Single-chain F Bioconjug. Chem. 8(3): 338		ates	mediate effici	ent lysis of f	olate	-receptor-p	positive tumor cells,"	
	AY	Christensen et al., "Memb 237-284 (1998).		for e	ndocytosis in	the renal pro	xima	l tubule,"	Int. Rev. Cytol. 180:	
	AZ	Citro, et al., "Inhibition of le antisense oligodeoxynucel							oduction of c-myb	
Examine <i>r</i>			Jones/			00., 00, 400-		te Ganside	<b>2/06</b> /8	
*EXAMINER	R: Initial	if reference considered, when	ther or not citati	on is	in conforman	ce with MPEF	609			
Draw line th	rough c	Itation if not in conformance a	and not consider	red. I	include copy of	of this form wi	th ne	xt commu	nication to applicant.	

						She	eet _2_ of _7		
	115	DEPARTMENT OF COMME	RCE	ATTY. DOG 20150-743		SERIAL 10/765.3			
	PATE	NT AND TRADEMARK OF	FICE	APPLICAN	APPLICANT Iontcho Vlahov et al.				
	INFORM	ATION DISCLOSURE STA	TEMENT		FILING DATE GROUP				
			U.S. PATENT	DOCUMENTS					
*Examiner		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate		
	BA								
	BB								
	BC						4		
	BD					ļ			
	BE		EODEIGN DATE	NT DOCUMENTS	<u> </u>	<u> </u>	_		
	1	Do All makes	Date	Country	Class	Subclass	Translation		
	L	Document Number	Date	Country	Class	Subciass	Yes No		
	BF BG		<del>  -</del>		-	<del> </del> -	<del> </del>		
	BH		+ +		<del> </del>	ļ	<del> </del>		
	BI					<u> </u>			
	BJ								
	ВК								
		OTHER REFERENCE				es, Etc.)			
	BL	Frankel, A.E., "Immunoto	kin therapy of can	cer," Oncology 7:	69 (1993)				
	ВМ	Garin-Chesa et al., "T immunopathology and m (1993).	olecular identifica	ation as a folate-l	binding protei	in," Am. J. Pat	hol. 142(2): 557-562		
	BN	Gottschalk, S., et al., "Fol enhanced gene expression	n," Gene Therap	y 1(3): 185-191 (1	994).		l disruption results in		
	BO	Hofland et al., "Folate-tar	geted gene transf	er in vivo," <i>Mol Th</i>	er 5(6): 739-7	744 (2002).			
	BP	Holladay et al., "Riboflavi Acta 1426(1): 195-204 (1)	999).	•					
	BQ	Holm, J., et al., "Folate re 17(4): 415-427 (1997).							
	BR	Holm, J., et al., "High-affii immunoreactivity, molecu 280(1): 267-271 (1991).	lar heterogeneity	and hydrophobic	domain of the	binding protein	n," Biochem J.		
	BS	Kamen et al., "Delivery of recycles," J. Biol. Chem.	263: 13602-13609	(1988).		•			
	BT	Kamen, B. A. and Capder content," Proc. Natl. Acad	l. Sci. USA 83: 59	83-5987 (1986).					
	BU	Kamen et al., "The folate J. Clin. Invest. 87(4): 144	2-1449 (1991).						
	BV	Kane et al., "The influence Partial characterization of (1986).	a membrane-ass	ociated methotres	kate binding p	rotein," J. Biol.	Chem. 261: 44-49		
	BW	Kranz et al., "Conjugates positive tumor cells for lys	is," Proc. Nati. Ad	ad. Sci. USA 92(	20), 9057-906	1 1995.			
	BX	Ladino et al., "Folate-may 864 (1997).	_	_					
	BY	Leamon, C. P. and Low, I Discovery Today 6: 36-43		liated targeting: fr	om diagnostic				
Examiner		/D. Jo				Date Consid 03/24			
		if reference considered, whi tation if not in conformance					inication to applicant.		

							She	et <u>3</u> o	f <u>7</u>
			ATTY. DOC			SERIAL 10/765,3			
		DEPARTMENT OF COMME INT AND TRADEMARK OF		20150-7435 APPLICAN			10//05,3	30	
	NEODIA	ATION DIROLOGUEE STAT	TEMPAIT	Iontcho VIa			GROUP		
	NFORM	ATION DISCLOSURE STAT	IEMENI	1/27/2004	FILING DATE 1/27/2004				
			U.S. PATENT	DOCUMENTS					
*Examiner Initial		Document Number	Date	Name	Class	Su	bclass	Filing Da if Approp	
	CA								
	CB								
	cc					1			
	CD		11_			ــــ			
	CE								
			FOREIGN PATER	NT DOCUMENTS				T	
		Document Number	Date	Country	Class	Su	bclass	Transla Yes	No No
	CF					╀			
	CG		<u> </u>		ļ. —-	╄			
	CH		<del>                                     </del>			╁			
	CI				ļ	-			
	CJ		1			+		ļ	
	CK	OTHER REFERENCE	350 # - 1 # - 1	# TW- D-4- f	Davidson & Davi		(n. )		
	I CL	OTHER REFERENCE Leamon, C. P. and Low, F	2.S "Cutotoxicity	of momordin-folat	e conjugates	in cu	tured hum	an cells."./	Biol.
		Chem. 267(35): 24966-24	971 (1992).						
	CM	Leamon, C. P. and Low, F receptor endocytosis," Pro	oc. Natl. Acad. Sci	i. USA 88(13): 55	72-5573 (199	11).			
	CN	Leamon, C. P. and Low, F endocytosis into cultured	cells," Biochem. J.	. 291: 855-860 (19	993).				
	co	Leamon, C. P. and Low, F Target. 2(2): 101-112 (199		rgeting of maligna	nt cells with o	cytoto	xin-folate o	conjugates,	' J. Drug
	CP	Leamon et al., "Folate-me 7(3): 157-169 (1999).	diated drug delive	ery: effect of altern	ative conjuga	ation	chemistry,"	J. Drug Ta	rget
	CQ	Leamon et al., "Synthesis Radiopharmaceutical," Bio				e-De	ived, (99m	)Tc-Based	
	CR	Leamon et al, "Cytotoxicit translocation domain," J. I				ward	tumor cells	. Contribut	on of
	cs	Lee et al., "Synthesis and Chem. 10(7): 2397-2414,	evaluation of taxo (2002).	ol-folic acid conjug	ates as targe	eted a	ntineoplas	tics," Bloom	y Med
	CT	Lee, R. J. and Huang, L., Tumor Cell-Specific Gene	"Folate-Targeted, Transfer," J. Biol.	Anionic Liposomo Chem. 271(14):	e-Entrapped 8481-8487 (1	Polyly 1996).	sine-Cond	lensed Dna	For
-	CU	Lee, R. J. and Low, P. S., Biochim. Biophys. Acta 12	"Folate-mediated 233: 134-144 (199	tumor cell targeti 5).	ng of liposom	ne-ent	rapped do:	xorubicin in	vitro,"
	CV	Lee, R. J. and Low, P. S, endocytosis," J. Biol. Che.			KB cells via	folate	receptor-r	nediated	
	CW	Lee et al, "Measurement of Biophys. Acta 1312(3): 23		ollowing Folate R	eceptor-Med	liated	Endocytos	sis," <i>Biochin</i>	7.
	СХ	Lewis et al., "Receptor-me Cancer Res. 58(14): 2952	?-2956 (1998). <sup>*</sup>						
	CY	Liu et al., "Targeted Drug Cytotoxicity Toward 5-FU-				rg. Ch	em. 66: 56	355-5 <del>6</del> 63 (2	
Examiner			Jones/				te Conside 03/24	red 4/2008	
*EXAMINER	t: Initial	if reference considered, who	other or not citation	n is in conforman	e with MPE	609		nigotion to	nnlicont

							eet <u>4</u> of <u>7</u>
	U.S. I	DEPARTMENT OF COMMER	RCE	ATTY. I 20150-	DOCKET NO. 74359	SERIAL 10/765,3	
		ENT AND TRADEMARK OFFI		APPLIC			
ľ	NFORM.	IATION DISCLOSURE STATE	EMENT	FILING	DATE	GROUP	
				1/27/20	04	1616	
			U.S. PATENT	DOCUMENT	s		
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	DA						I
	DB	ļ	<del></del>			ļ	
	DC DD	<b></b>	+			<del> </del>	-
	DE	<del>                                     </del>	+		-	<del> </del>	-
			FOREIGN PATE	NT DOCUME	NTS	L	-
		Document Number	Date	Country	Class	Subclass	Translation Yes No
	DF						
	DG						
	DH		$\Box$				
	DI						
	DJ		I I	TW- D-	Series Box	<u></u>	
	I DK	OTHER REFERENCE					munotherapy of
		syngeneic murine tumors,"	Cancer Immuno	ol Immunother	·51: 153-162 (200	02).	
	DL	Lu et al., "Folate-targeted e prodrug," J. Drug Target 7(	(1): 43-53 (1999).	).			
	DM	Lu, J. Y. and Low, P. S., "Fo Drug Del Rev 54(5); 675-69	olate-mediated o	delivery of ma	cromolecular anti-	cancer therape	utic agents," Adv.
	DN	Luo et al., "Efficient synthes differentiated derivatives of	ses of pyrofolic a	m. Chem. Soc	. 119: 10004-100	13 (1997).	· ·
	DO	Mathals et al., "Synthesis o radiopharmaceutical," Bioce	of [(99m)Tc]DTPA conjug Chem. 11(	A-folate and it (2): 253-257 (2	s evaluation as a 2000).	folate-receptor-	
	DP	Mathais et al., "Receptor-m KB tumor xenografts," Nucl	nediated targeting I Med Biol 26(1):	g of 67Ga-def 23-25 (1999)	feroxamine-folate		
	DQ	Mathias, C. J. and Green, M receptor-targeted radiophar	rmaceutical," Nu	ıcı. Med. Biol.	25(6): 585-587 (1	1998).	
	DR	Mathias et al., "Tumor-Sele Gallium-67-Deferoxamine-f	Folate," J. Nucl. I	Med. 37(6): 10	003-1008 (1996).	•	
	DS	Mathias et al., "Indium- 111 Nucl. Med. 39(9): 1579-158	85 (1998).				
	DT	Matsui et al., "Studies on m 189-198 (1968).					
	DU	Melani et al., "Targeting of i antifolate receptor antibody	y," Cancer Res. 5	58(18): 4146-4	4154 (1998).		
	DV	Melby et al., "Entry of prote	•				
	DW	Mislick et al., "Transfection Chem. 6(5): 512-515 (1995	5).				
	DX	Morshed et al., "Folate tran cultured human proximal tu	ubule cells," J. Na	utr. 127(6): 11	137-1147 (1997).		-
	DY	Olsnes, et al., "Immunotoxii (1989).	•	alls and mech	anisms of action,		
Examiner		/D. Jos	nes/			Date Soneid	608d
		if reference considered, whet					unication to applicant.

						Sh	eet <u>5</u> of <u>7</u>
			505	ATTY, DO			ubclass Translation Yes No  Telexus Tumors of Sv40  Jival of animals bearing pump and a probenecid- Biophys. Acia 1222(2): 309  way, J Control Release," 74(1- teptor-mediated gene therapy,"  J. Cell Biol. 132(1-2): 35-47  slignant tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (1994).  To control tissues in vivo and in 2-2443, (
		DEPARTMENT OF COMME ENT AND TRADEMARK OF		20150-743 APPLICAN	IT	10/700,	330
	NEODN	IATION DISCLOSURE STAT	TEMENT	Iontcho Via		LOBOUR	
	NEORIV	ATTON DISCLOSURE STAT	LIVILIAI	1/27/2004			
			U.S. PATENT	DOCUMENTS			
*Examiner		Document Number	Date	Name	Class	Subclass	
Initial	EA	Document Humber	-		1	-	If Appropriate
	EB		+			1	
-	EC		1			†	
	ED		1		1		
	EE		1	,			
			FOREIGN PATE	NT DOCUMENTS	s		
		Document Number	Date	Country	Class	Subclass	
	EF						
	EG					ļ	
	EH					ļ	
	EI		-				
	EJ		1 1			-	
	I EK	OTHER REFERENCE					nom of Sud0
		Transgenic Mice," J. Neur	ooncol. 32(2): 11	1-123 (1997).			
	EL	endogenously arising brai	n tumors," Int. J.	Cancer 78(4): 47	0-79 (1998).		
	EM	sensitive folate transporte (1994).	r in human place	ntal choriocarcino	ma cells," Bio	ochim. Biophys	. Acta 1222(2): 309
	EN	3): 77-82 (2001).					
	EO	J. Pharm. Sci 88(11): 111:	2-1118 (1999).	,			
	EP	(1996).					
	EQ	established cell lines. Phy	siologic and clini	cal implications,"	Cancer 73(9):	2432-2443, (1	994).
	ER	Rothberg et al, "Cholester 5-methyltetrahydrofolate,"	ol controls the cli J. Cell Biol. 111	ustering of the gly (6): 2931-2938 (19	cophospholip 390).	id-anchored m	embrane receptor for
	EŜ	Rothberg et al., "The glyce coated pit endocytic pathy	ophospholipid-lin vay," <i>J. Cell Biol</i> .	ked folate recepto 110(3): 637-649 (	r internalizes (1990).	folate without	entering the clathrin-
	ET	76(5): 761-66 (1998).					
	EU	Sadasivan et al., "The con determined from the cDN/	A," J. Biol. Chem.	264: 5806-5811,	(1989).		
	EV	Carbamate Disulfides," J.	Org. Chem. 55: 2	2975-2978 (1990)			•
	EW	caveolae," J. Cell Biol. 12-	4(3): 307-313 (19	94).			_
	EX	Biol. 134(5): 1169-1177 (1	1996).	-	-		
	EY	Li et al "Targeted delivery	or antisense olig	oaeoxynucleofide	s by LPDII," .		
Examiner		/D. Jone	s/				
*EXAMINER Draw line to	R: Initial	if reference considered, who itation if not in conformance	ether or not citation and not consider	on is in conformar red. Include copy	of this form v	P 609. vith next comm	unication to applicant.

						She	eet <u>6</u> of <u>7</u>		
		DEPARTMENT OF COMM		ATTY. DOC 20150-743	359	SERIAL 10/765,			
	PAII	ENT AND TRADEMARK OF	FICE	APPLICAN Iontcho Via					
	INFORM	MATION DISCLOSURE STA	TEMENT	FILING DA 1/27/2004	ATE	GROUP 1616			
			U.S. PATENT	T DOCUMENTS					
*Examiner	г	Document Number	Date	Name	ame Class S		Filing Date if Appropriate		
	FA								
	FB								
	FC		+						
	FD					4			
	FE								
			FOREIGN PATE	ENT DOCUMENTS			Translation		
		Document Number	Date	Country	Class	Subclass	Yes No		
	FF				Ţ				
	FG		$\rightarrow$						
	FH		++		<del></del>	<del></del>			
	FI		<del></del>			<del></del>			
	FJ	071150 0555051		" - T#- D-4-					
	FK	OTHER REFEREN					robeterocyclic		
		Phosphoramidates as Fo	plate Receptor-Tar	rgeted Alkylating A	Agents," J. Me	ed. Chem. 44: 6	9-73 (2001).		
	FL	Toffoli et al., "Overexpression of folate binding protein in ovarian cancers," Int. J. Cancer 74(2): 193-198 (1997). Turek et al., "Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells," J. Cell Sci. 106:							
	FM	423-430 (1993).	•						
	FN	Turk et al., "Characteriza liposomes at endosomal	pHs," Biochim Bio	ophys Acta 1559(1	1): 56-68 (200	02).			
	FO	Varma, R. and Mayor, S. 394(6695): 798-801 (199	98).	•					
	FP		Vyas, D., et al., "A practical synthesis of mitomycin A and its analogs," J Org Chem 31:4307-4309 (1986)						
	FQ	Compartments," J. Am. 0	Vogel et al., "Peptide-Mediated Release of Folate-Targeted Liposome Contents From Endosomal Compartments," J. Am. Chem. Soc. 118(7): 1581-1586 (1996).						
	FR	Wang, S. and Low, P. S. acids to cancer cells," J.	Control Rel 53(1-3	3): 39-48 (1998).					
	FS	Wang et al., "Delivery of receptor into cultured KB Sci. USA 92(8): 3318-33.	cells with liposom 22 (1995).	nes conjugated to t	folate via pol	lyethylene glycol	I," Proc. Natl. Acad.		
	FT	Wang et al., "Synthesis, radiopharmaceutical for t	tumor imaging," Bi	ioconj. Chem. 7(1)	): 56-62 (1996	6).			
	FU	Wang et al., "Design and Bioconjug Chem. 8(5): 6	73-679 (1997).				and the second		
	FV	Weitman et al., Distributi Res., 52(12), 3396-3401	, 1992.						
	FW	Weitman et al., "Cellular homeostasis," Cancer Re	es. 52(23): 6708-6	5711 (1992).		,			
	FX	Wiener et al., "Targeting receptor," Invest. Radiol.	. 32(12): 748-54 (1	1997).					
	FY	Wu et al., "Clustering of to caveolin," J. Membr. Biol			andent of both				
Examiner		/D. Jones/				Date Consid 03/24/			
		I if reference considered, who citation if not in conformance					inication to applicant.		

							et <u>7 of 7</u>	
	11.0	DEPARTMENT OF COMME	PCE	ATTY. DOCKET NO. SERIAL 20150-74359 10/765,3			L NO.	
		ENT AND TRADEMARK OF		APPLICAN Iontcho VIa				
	INFORM	ATION DISCLOSURE STAT	EMENT	FILING DA 1/27/2004		GROUP 1616		
			U.S. PATENT	DOCUMENTS				
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
	GA							
	GB							
	GC				ļ			
	GD							
	ĢE				J	<u> </u>	J	
	r		FOREIGN PATE	NT DOCUMENTS	3		Translation	
		Document Number	Date	Country	Class	Subclass	Yes No	
	GF							
	GG		ļ			<u> </u>	<del></del>	
	GH							
	GI				ļ	-	<del></del>	
	GJ	OTHER REFERENC	SE (Including Au	ther Title Date	Portingnt Pac	see Etc.)	I	
	GK	Zimmerman, J., "Folic acid	d transport in orga	an-cultured mucos			nce for distinct	
	GL	carriers," Gastroenterol. 9	9(4): 964-972 (19	90).				
	GM							
	GN							
	GO							
	GP							
	GQ							
	GR							
	GS							
	GT							
	GU							
	GV							
	GW							
	GX							
	GY							
	Ľ.							
Examiner		/D. Jones/				Date Consid 03/24/20	ered )8	
*EXAMINER Draw line th	R: Initial	if reference considered, whe	ther or not citatio	n is in conforman	ce with MPE	609.	nication to applicant	